Blue Gene Used to Examine Dewetting in Protein Folding


By Salvatore Salamone Bio-IT World

Researchers at IBM’s Thomas J. Watson Research Center and Columbia University have used a small (single-rack) Blue Gene system from IBM to discover a new phenomenon having to do with the folding of a melittin protein in water.

Specifically, the Blue Gene system’s processing power allowed the researchers to perform simulations that were impractical to run on previously available high-performance computing systems.

In their simulations, the researchers studied what is called the dewetting process associated with the folding of a melittin protein tetramer in water. The focus of the simulations was to look at variations in the folding process under different conditions.

Understanding the mechanisms of melittin folding in water has implications in several areas. For instance, melittin inhibits lipid-protein interactions in some membranes (See: “Effects of melittin on lipid-protein interactions in sarcoplasmic reticulum membranes,” Biophysics Journal, vol. 63, page 1513, 1992.)

Melittin is a small protein that forms a needle-like shape in water. This shape allows it to puncture cell membranes. (Melittin is a component of bee venom, and this cell-puncturing characteristic helps deliver other venomous ingredients -- particularly the disruptive enzyme phospholipase A -- into a cell.)

The science behind the IBM and Columbia University simulations has to do with the way melittin folds. The protein is self-folding and the researchers were looking at the role a thin layer of water (within the folding protein) plays as the folding process takes place.

Essentially, there is a very small channel (i.e., nanoscale-sized; about the width of a few molecules) of water that influences the folding process. The dewetting process investigated has to do with the water layer drying out, leading to a collapse of the protein unto itself.

The simulations varied the channel size and other conditions. “We ran many different configurations,” says Ruhong Zhou, of the Computational Biology Center at IBM’s Thomas J. Watson Research Center. “We used ten different melittin protein sequences with ten different starting configurations each -- so 100 simulations all together.”

He notes that the key to doing each simulation (and the large number of simulations) was Blue Gene’s processing power. “We ran the simulations on a single-rack system with about a thousand [processing] nodes,” says Zhou. “In the past, simulations on similar systems took about 20 weeks of CPU time to run. With the single rack Blue Gene, we were able to reduce this to one week.” 

The simulations give researchers the ability to better understand the basic science involved in protein folding. In fact, Zhou and his colleagues found a mechanism that switched the channel from wet to dry. “This was not expected for real protein systems,” says Zhou. “It’s a new phenomenon we’re seeing.” 

The findings were published in the recent issue of Nature. (“Observation of dewetting transition in the collapse of the melittin tetramer,” Nature, September 1, 2005, Volume 437, Number 7055, p.159.)

Besides Zhou, the others involved in this research project are Pu Liu (the paper’s lead author) and Xuhui Huang (both of the Department of Chemistry at Columbia University) and B.J. Berne of the Department of Chemistry at Columbia University and the IBM Thomas J. Watson Research Center.

Related Stories:

New Blue Gene Project to Model the Brain

First Blue Gene Paper Published

IBM, SGI Earn Top Bragging Rights at SC2004

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.